Roche’s Tecentriq meets primary endpoints in Phase III lung cancer trial
September 1, 2016Research and Development PD-L1, Roche, keytruda, nivolumab, opdivo, phase III, tecentriq
Roche has presented new Phase III data for cancer immunotherapy Tecentriq (atezolizumab), which shows a clinically meaningful improvement in overall …
Pfizer nabs EU approval for Xalkori for certain lung cancers
August 31, 2016Sales and Marketing Pfizer, Xalkori, lung cancer, non-small cell lung cancer
The European Commission has approved Pfizer’s Xalkori (crizotinib) for the treatment of adults with ROS1-positive advanced non-small cell lung cancer …
Recipharm establishes long term supply agreement with Tillotts Pharma AG
August 31, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Recipharm, the contract development and manufacturing organisation (CDMO), announces that it has entered into a long term supply agreement with …
The September issue of Pharmafocus is now live!
August 31, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myer's Squibb, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, Cloud Computing, Pharmafocus, Pharmafocus new issue, brexit, clinical trial transparaency, opdivo
The latest edition of Pharmafocus is available online now. In this issue, we explore the future of the clinical trial …
AstraZeneca to pay £5.52 million to settle bribery probe
August 31, 2016Research and Development AstraZeneca, SEC, misconduct
According to US regulators, AstraZeneca is to pay $5.52 million to resolve a foreign bribery probe investigating payments made to …
FDA approves Novartis Enbrel biosimilar
August 31, 2016Research and Development, Sales and Marketing Enbrel, FDA, Novartis, Sandoz, biosimilar, erzeli
Novartis, through its Sandoz division, has announced that the FDA has approved Erelzi (etanercept-szzs), a biosimilar of Amgen’s blockbuster drug …
Teva to lay off 236 in Pomona, New York
August 30, 2016Manufacturing and Production, Research and Development Teva, closure
Teva is currently in the process of winding down operations at its manufacturing plant in Pomona, New York as it …
UK asthma spending tops £1.1 billion
August 30, 2016Research and Development asthma, university of edinburgh
The University of Edinburgh has released a report that claims UK health service spending on asthma has reached £1.1 billion …
KaloBios cuts ties with former CEO Martin Shkreli, outlines ‘maniacal’ turnaround plan
August 30, 2016Research and Development, Sales and Marketing Daraprim, KaloBios, Martin Shkreli, Retrophin, benznidazole, turnaround
Two months after small drugmaker KaloBios returns from bankruptcy, controversial industry figure Martin Shkreli is no longer a stakeholder in …
Heart disease drug development is falling
August 30, 2016Manufacturing and Production, Research and Development cardiovascular disease, heart disease, research and development
The number of drugs currently in development to combat heart disease has fallen in the last 20 years, it has …
Cipla receives FDA approval for generic version of Valeant antidepressant
August 30, 2016Manufacturing and Production, Sales and Marketing Cipla, FDA, Valeant, Wellbutrin
Indian multinational pharma and biotech company Cipla has announced that its US arm InvaGen Pharmaceuticals has received approval from the …
Amgen’s Prolia achieves positive top-line Phase III results after 12 months
August 30, 2016Manufacturing and Production, Research and Development Amgen, Prolia, denosumab, phase III
Amgen has announced that its drug Prolia (denosumab) generated positive Phase III results investigating its safety and efficacy in patients …
Sanofi & Regeneron’s Praluent cholesterol treatment smashes Phase III target
August 30, 2016Manufacturing and Production, Research and Development Regeneron, Sanofi, apheresis, cholesterol, phase III
Sanofi and Regeneron have announced that their Praluent injection generated positive Phase III results investigating patients with an inherited form …
Vectura asthma treatment fails at Phase III
August 30, 2016Manufacturing and Production, Research and Development asthma, inhaler, phase III, phase III failure, vectura
Respiratory drug specialist Vectura’s asthma treatment Flutiform was unsuccessful in meeting the primary endpoint in its Phase III trial conducted …
Top ten stories in the pharmaceutical industry this week
August 26, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharmafile, top 10
If this week left you feeling with a sense of déjà vu, you could certainly be forgiven. With US politicians …
EMA accepts regulatory submission for proposed Herceptin biosimilar
August 26, 2016Medical Communications Biocon, EMA, Herceptin, Mylan, biosimilar, regulatory, submission, trastuzumab
Mylan and Biocon have announced that the European Medicines Agency (EMA) has accepted for review its marketing authorisation application for …
Denali Therapeutics secures another $130 million for neurodegenerative disease research
August 26, 2016Medical Communications
Denali Therapeutics has announced a string of collaborations and financing deals worth $130 million that will see the biotech, which …
Jobs to go at Takeda as it shuts down Cambridge facility
August 26, 2016Manufacturing and Production, Medical Communications Cambridge, Jobs, Takeda, closure
Takeda has announced plans to close its facility in Cambridge in the UK, to refocus its research and development operations …
Mylan announces immediate plans to cut price of EpiPen
August 25, 2016Medical Communications, Research and Development Mylan, clinton, epipen, increase
Subject to intense pressure over the last few days, Mylan has made an attempt to avoid becoming “another Valeant” by …
Boost for Clovis as FDA grants priority review for rucaparib in ovarian cancer
August 25, 2016Research and Development, Sales and Marketing FDA, clovis, ovarian cancer, rucaparib
Clovis Oncology has announced that the US Food and Drug Administration has accepted its new drug application for rucaparib, and …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
